https://hartajsingh1.substack.com/archivedailyhttps://hartajsingh1.substack.com/aboutweeklyhttps://hartajsingh1.substack.com/podcastweeklyhttps://hartajsingh1.substack.com/p/the-expectations-game-playing-biogens2026-09-11monthlyhttps://hartajsingh1.substack.com/p/video-companion-moderna-and-the-expectations2026-09-09monthlyhttps://hartajsingh1.substack.com/p/the-expectations-game-when-good-businesses2026-09-07monthlyhttps://hartajsingh1.substack.com/p/tape-check-stepping-back-to-see-the2026-09-06monthlyhttps://hartajsingh1.substack.com/p/the-biotech-capital-compass-august2026-09-04monthlyhttps://hartajsingh1.substack.com/p/video-companion-understanding-short2026-09-02monthlyhttps://hartajsingh1.substack.com/p/tape-check-a-year-can-change-a-lot2026-08-30monthlyhttps://hartajsingh1.substack.com/p/video-recap-six-months-that-tested2026-08-28monthlyhttps://hartajsingh1.substack.com/p/the-long-climb-assembly-biosciences2026-08-27monthlyhttps://hartajsingh1.substack.com/p/video-recap-from-excess-to-execution2026-08-25monthlyhttps://hartajsingh1.substack.com/p/tape-check-the-poster-child-returns2026-08-23monthlyhttps://hartajsingh1.substack.com/p/video-companion-alnylam-after-the2026-08-20monthlyhttps://hartajsingh1.substack.com/p/video-companion-beyond-the-fed2026-08-19monthlyhttps://hartajsingh1.substack.com/p/tape-check-beyond-the-fed2026-08-16monthlyhttps://hartajsingh1.substack.com/p/video-recap-alnylam-the-diamond-and2026-08-14monthlyhttps://hartajsingh1.substack.com/p/biotech-watchlist-crispr-therapeutics2026-08-12monthlyhttps://hartajsingh1.substack.com/p/tape-check-what-short-interest-is2026-08-09monthlyhttps://hartajsingh1.substack.com/p/biotech-watchlist-beyond-journavx2026-08-07monthlyhttps://hartajsingh1.substack.com/p/video-companion-july-tape-checks2026-08-05monthlyhttps://hartajsingh1.substack.com/p/video-companion-contingent-value2026-08-04monthlyhttps://hartajsingh1.substack.com/p/the-biotech-capital-compass-july2026-08-18monthlyhttps://hartajsingh1.substack.com/p/the-biotech-tape-check-valuation2026-08-03monthlyhttps://hartajsingh1.substack.com/p/the-long-climb-novavax-and-the-challenge2026-07-31monthlyhttps://hartajsingh1.substack.com/p/video-recap-phase-3-reality-checklooking2026-07-29monthlyhttps://hartajsingh1.substack.com/p/video-companion-the-overlooked-economics2026-07-28monthlyhttps://hartajsingh1.substack.com/p/the-biotech-tape-check-buying-the2026-07-26monthlyhttps://hartajsingh1.substack.com/p/video-companion-thermo-fisher-and2026-07-23monthlyhttps://hartajsingh1.substack.com/p/the-long-climb-building-the-bridge2026-07-21monthlyhttps://hartajsingh1.substack.com/p/the-biotech-tape-check-is-biotechnology2026-08-03monthlyhttps://hartajsingh1.substack.com/p/the-skeptical-lens-competition-creates2026-07-16monthlyhttps://hartajsingh1.substack.com/p/the-biotech-tape-check-following2026-07-13monthlyhttps://hartajsingh1.substack.com/p/video-recap-vertex-pharmaceuticals2026-07-12monthlyhttps://hartajsingh1.substack.com/p/video-companion-regeneron-revisiting2026-07-09monthlyhttps://hartajsingh1.substack.com/p/reading-the-diamond-alnylams-investment2026-07-07monthlyhttps://hartajsingh1.substack.com/p/bcc-now-and-then-part-2-when-the2026-07-05monthlyhttps://hartajsingh1.substack.com/p/video-companion-reading-the-biotech2026-07-02monthlyhttps://hartajsingh1.substack.com/p/video-recap-biotech-into-2026-the-2a42026-07-01monthlyhttps://hartajsingh1.substack.com/p/the-investor-exchange-polypid-and2026-06-30monthlyhttps://hartajsingh1.substack.com/p/the-biotech-tape-check-a-broadening2026-07-13monthlyhttps://hartajsingh1.substack.com/p/the-biotech-tape-check-stabilization2026-07-08monthlyhttps://hartajsingh1.substack.com/p/video-companion-pharma-as-defense2026-06-21monthlyhttps://hartajsingh1.substack.com/p/the-skeptical-lens-when-competition2026-06-19monthlyhttps://hartajsingh1.substack.com/p/video-recap-the-skeptical-lens-not2026-06-17monthlyhttps://hartajsingh1.substack.com/p/the-biotech-tape-check-separating2026-06-15monthlyhttps://hartajsingh1.substack.com/p/video-companion-the-china-biotech2026-06-14monthlyhttps://hartajsingh1.substack.com/p/bcc-then-and-now-part-1-revisiting2026-06-12monthlyhttps://hartajsingh1.substack.com/p/the-biotech-watchlist-from-asco-20262026-06-11monthlyhttps://hartajsingh1.substack.com/p/video-companion-the-cost-of-survival2026-06-09monthlyhttps://hartajsingh1.substack.com/p/the-biotech-watchlist-the-china-biotech2026-06-04monthlyhttps://hartajsingh1.substack.com/p/biotech-watchlist-asco-ends-volatility2026-06-18monthlyhttps://hartajsingh1.substack.com/p/precigen-inovio-and-the-challenge2026-05-29monthlyhttps://hartajsingh1.substack.com/p/video-recap-gileads-oncology-platform2026-05-27monthlyhttps://hartajsingh1.substack.com/p/the-cost-of-survival-from-financing2026-06-09monthlyhttps://hartajsingh1.substack.com/p/how-biopharma-works-part-2-vertex2026-05-24monthlyhttps://hartajsingh1.substack.com/p/biotech-blueprint-x-biotech-capital2026-05-22monthlyhttps://hartajsingh1.substack.com/p/how-biopharma-works-part-1-roche2026-05-21monthlyhttps://hartajsingh1.substack.com/p/biotech-tape-check-may-2026-video2026-05-20monthlyhttps://hartajsingh1.substack.com/p/the-skeptical-lens-part-3-thermo2026-05-19monthlyhttps://hartajsingh1.substack.com/p/biotech-tape-check-rates-volatility2026-06-02monthlyhttps://hartajsingh1.substack.com/p/video-companion-biogen-turning-the2026-05-15monthlyhttps://hartajsingh1.substack.com/p/the-skeptical-lens-part-2-when-competition2026-05-13monthlyhttps://hartajsingh1.substack.com/p/video-recap-the-hidden-infrastructure2026-05-12monthlyhttps://hartajsingh1.substack.com/p/video-companion-not-all-competition2026-05-10monthlyhttps://hartajsingh1.substack.com/p/biogen-turning-the-cornerbut-still2026-05-08monthlyhttps://hartajsingh1.substack.com/p/video-companion-the-deal-window-before2026-05-06monthlyhttps://hartajsingh1.substack.com/p/the-skeptical-lens-not-all-competition2026-05-03monthlyhttps://hartajsingh1.substack.com/p/video-recap-why-medical-conference2026-04-29monthlyhttps://hartajsingh1.substack.com/p/the-deal-window-before-the-deal-becomes2026-04-28monthlyhttps://hartajsingh1.substack.com/p/video-companion-vertex-crispr-and2026-04-26monthlyhttps://hartajsingh1.substack.com/p/crispr-therapeutics-from-first-approval2026-04-23monthlyhttps://hartajsingh1.substack.com/p/the-cost-of-survival-from-drug-pricing2026-04-22monthlyhttps://hartajsingh1.substack.com/p/video-companion-vertex-biotech-and2026-04-19monthlyhttps://hartajsingh1.substack.com/p/vertex-pharmaceuticals-part-2-still2026-04-17monthlyhttps://hartajsingh1.substack.com/p/video-recap-artificial-intelligence2026-04-14monthlyhttps://hartajsingh1.substack.com/p/biotech-tape-check-a-more-selective2026-04-12monthlyhttps://hartajsingh1.substack.com/p/video-companion-novavax-platform2026-04-10monthlyhttps://hartajsingh1.substack.com/p/video-recap-vertex-before-the-next2026-04-08monthlyhttps://hartajsingh1.substack.com/p/video-the-cost-of-survival-the-one2026-04-05monthlyhttps://hartajsingh1.substack.com/p/novavax-at-the-crossroads2026-04-03monthlyhttps://hartajsingh1.substack.com/p/video-recap-novavax-stabilized-but2026-04-01monthlyhttps://hartajsingh1.substack.com/p/the-cost-of-survival-part-1-when2026-04-14monthlyhttps://hartajsingh1.substack.com/p/video-companion-gileads-repricing2026-03-29monthlyhttps://hartajsingh1.substack.com/p/regeneron-from-franchise-to-platforms2026-03-27monthlyhttps://hartajsingh1.substack.com/p/video-recap-regenerons-bet-on-quality2026-03-24monthlyhttps://hartajsingh1.substack.com/p/gilead-oncology-proof-in-progress2026-03-22monthlyhttps://hartajsingh1.substack.com/p/video-companion-biotech-tape-check2026-03-20monthlyhttps://hartajsingh1.substack.com/p/video-recap-kite-pharma-and-the-cell2026-03-18monthlyhttps://hartajsingh1.substack.com/p/biotech-tape-check-consolidation2026-03-17monthlyhttps://hartajsingh1.substack.com/p/gileads-repricing-moment2026-03-15monthlyhttps://hartajsingh1.substack.com/p/video-recap-the-evolution-of-gileads2026-03-12monthlyhttps://hartajsingh1.substack.com/p/video-companion-roche-revisited-why2026-03-08monthlyhttps://hartajsingh1.substack.com/p/video-recap-cancer-vaccines-and-the2026-03-06monthlyhttps://hartajsingh1.substack.com/p/pharma-as-defense-biotech-as-barometer2026-03-03monthlyhttps://hartajsingh1.substack.com/p/video-companion-eikon-therapeutics2026-03-01monthlyhttps://hartajsingh1.substack.com/p/video-recap-drug-development-basics2026-02-27monthlyhttps://hartajsingh1.substack.com/p/roche-revisited-the-core-holding2026-02-25monthlyhttps://hartajsingh1.substack.com/p/video-companion-mrna-recalibration2026-02-22monthlyhttps://hartajsingh1.substack.com/p/the-deal-window-eikon-therapeutics-0e52026-02-20monthlyhttps://hartajsingh1.substack.com/p/the-deal-window-eikon-therapeutics-2812026-02-19monthlyhttps://hartajsingh1.substack.com/p/video-recap-roche-a-core-holding2026-02-18monthlyhttps://hartajsingh1.substack.com/p/video-recap-phase-3-binaries-through2026-02-16monthlyhttps://hartajsingh1.substack.com/p/quantifying-the-canary-biotech-rates2026-02-12monthlyhttps://hartajsingh1.substack.com/p/video-recap-when-biotech-weakness2026-02-12monthlyhttps://hartajsingh1.substack.com/p/the-skeptical-lens-from-excess-to2026-02-10monthlyhttps://hartajsingh1.substack.com/p/the-skeptical-lens-artificial-intelligence2026-02-08monthlyhttps://hartajsingh1.substack.com/p/the-skeptical-lens-the-recalibration2026-02-06monthlyhttps://hartajsingh1.substack.com/p/phase-3-reality-check-why-binary2026-02-05monthlyhttps://hartajsingh1.substack.com/p/biotech-tape-check-post-jpm-pre-spring2026-02-01monthlyhttps://hartajsingh1.substack.com/p/the-deal-window-eikon-therapeutics2026-01-30monthlyhttps://hartajsingh1.substack.com/p/how-we-read-biotech-earnings-in-an2026-01-28monthlyhttps://hartajsingh1.substack.com/p/video-companion-krystal-biotech-when2026-01-26monthlyhttps://hartajsingh1.substack.com/p/krystal-biotech-when-execution-becomes2026-01-23monthlyhttps://hartajsingh1.substack.com/p/video-recap-biotech-into-2026-the2026-01-22monthlyhttps://hartajsingh1.substack.com/p/video-companion-jpm-2026-from-narrative2026-01-21monthlyhttps://hartajsingh1.substack.com/p/jpm-2026-from-narrative-repair-to2026-01-19monthlyhttps://hartajsingh1.substack.com/p/video-companion-the-vertex-framework2026-01-16monthlyhttps://hartajsingh1.substack.com/p/video-recap-why-san-francisco-healthcare2026-01-14monthlyhttps://hartajsingh1.substack.com/p/vertex-revisited-execution-takes2026-01-14monthlyhttps://hartajsingh1.substack.com/p/why-china-now-making-sense-of-chinas2026-01-12monthlyhttps://hartajsingh1.substack.com/p/why-san-francisco-healthcare-conference2026-01-11monthlyhttps://hartajsingh1.substack.com/p/the-birth-of-chinas-innovation-biopharma2026-01-09monthlyhttps://hartajsingh1.substack.com/p/the-15-month-biotech-stress-test2026-01-06monthlyhttps://hartajsingh1.substack.com/p/biotech-into-2026-the-calendar-the2026-01-06monthlyhttps://hartajsingh1.substack.com/p/rewinding-the-tape-the-most-read2025-12-31monthlyhttps://hartajsingh1.substack.com/p/video-recap-from-setup-to-reality2025-12-30monthlyhttps://hartajsingh1.substack.com/p/china-biopharma-from-policy-to-pipeline2025-12-30monthlyhttps://hartajsingh1.substack.com/p/video-recap-biotech-in-three-dimensions2025-12-30monthlyhttps://hartajsingh1.substack.com/p/video-recap-chinas-innovation-202025-12-24monthlyhttps://hartajsingh1.substack.com/p/so-you-want-to-be-a-biotech-entrepreneur2025-12-22monthlyhttps://hartajsingh1.substack.com/p/gileads-hiv-portfolio-extending-leadership2025-12-19monthlyhttps://hartajsingh1.substack.com/p/biogen-at-the-crossroads-part-two2025-12-16monthlyhttps://hartajsingh1.substack.com/p/biogen-at-the-crossroads-commercial2025-12-16monthlyhttps://hartajsingh1.substack.com/p/restoring-the-core-of-diabetes2025-12-12monthlyhttps://hartajsingh1.substack.com/p/regenerons-reset-part-two-from-retina2025-12-11monthlyhttps://hartajsingh1.substack.com/p/regenerons-reset-expectations-reality2025-12-08monthlyhttps://hartajsingh1.substack.com/p/two-paths-through-friedreichs-ataxia2025-12-04monthlyhttps://hartajsingh1.substack.com/p/video-recap-rrps-first-drug-arrivesand2025-11-30monthlyhttps://hartajsingh1.substack.com/p/biotech-in-review-what-we-saw-coming2025-11-26monthlyhttps://hartajsingh1.substack.com/p/quince-at-the-turning-point2025-11-25monthlyhttps://hartajsingh1.substack.com/p/video-recap-where-biotech-really2025-11-22monthlyhttps://hartajsingh1.substack.com/p/biotech-in-three-dimensions-prices2025-11-20monthlyhttps://hartajsingh1.substack.com/p/when-rates-move-biotech-breathes2025-11-19monthlyhttps://hartajsingh1.substack.com/p/sarepta-q3-2025-context-correction2025-11-18monthlyhttps://hartajsingh1.substack.com/p/video-recap2025-11-12monthlyhttps://hartajsingh1.substack.com/p/investor-exchange-the-q-and-a-edition2025-11-11monthlyhttps://hartajsingh1.substack.com/p/the-state-of-biotech-from-breakneck2025-11-11monthlyhttps://hartajsingh1.substack.com/p/biotech-watchlist-reprogramming-autoimmunity2025-11-08monthlyhttps://hartajsingh1.substack.com/p/video-recap-inside-the-hiv-revolution2025-11-03monthlyhttps://hartajsingh1.substack.com/p/inside-the-mrna-revolution-part-ii2025-10-30monthlyhttps://hartajsingh1.substack.com/p/video-recap-united-therapeutics-second2025-10-29monthlyhttps://hartajsingh1.substack.com/p/biotech-watchlist-inside-kite-pharmas2025-10-26monthlyhttps://hartajsingh1.substack.com/p/video-recap-syndaxs-shift-from-promise2025-10-21monthlyhttps://hartajsingh1.substack.com/p/sareptas-reset-between-safety-lessons2025-10-17monthlyhttps://hartajsingh1.substack.com/p/video-recap-biotechs-next-act-clarity2025-10-15monthlyhttps://hartajsingh1.substack.com/p/video-recap-biotechs-fourth-quarter2025-10-13monthlyhttps://hartajsingh1.substack.com/p/biotechs-next-act-clarity-amid-the2025-10-12monthlyhttps://hartajsingh1.substack.com/p/biotechs-fourth-quarter-pulse-from2025-10-09monthlyhttps://hartajsingh1.substack.com/p/the-deal-monthly-capital-valuation2025-10-01monthlyhttps://hartajsingh1.substack.com/p/inside-the-mrna-revolution-history2025-09-26monthlyhttps://hartajsingh1.substack.com/p/biotech-and-poker-playing-the-odds2025-09-24monthlyhttps://hartajsingh1.substack.com/p/tyvaso-in-ipf-what-changed-and-whats2025-09-19monthlyhttps://hartajsingh1.substack.com/p/immunotherapy-advances-in-rrp-precigen2025-09-17monthlyhttps://hartajsingh1.substack.com/p/video-recap-recovery-risks-and-reality2025-09-15monthlyhttps://hartajsingh1.substack.com/p/syndax-execution-meets-expansion2025-09-13monthlyhttps://hartajsingh1.substack.com/p/video-recap-biotech-in-transition2025-09-08monthlyhttps://hartajsingh1.substack.com/p/a-breath-of-fresh-momentum-for-united2025-09-03monthlyhttps://hartajsingh1.substack.com/p/biotech-in-transition-signs-of-a2025-09-03monthlyhttps://hartajsingh1.substack.com/p/atyr-pharma-a-pivotal-test-in-sarcoidosis2025-08-26monthlyhttps://hartajsingh1.substack.com/p/regeneron-pipeline-strength-vs-execution2025-08-22monthlyhttps://hartajsingh1.substack.com/p/biotechs-capital-hunger-games-from2025-08-15monthlyhttps://hartajsingh1.substack.com/p/vertex-at-a-crossroads-core-strength2025-08-13monthlyhttps://hartajsingh1.substack.com/p/biotechs-balancing-act-technical2025-08-08monthlyhttps://hartajsingh1.substack.com/p/akeso-revisited-from-local-leader2025-08-03monthlyhttps://hartajsingh1.substack.com/p/between-hope-and-hazard-sarepta-gene2025-07-31monthlyhttps://hartajsingh1.substack.com/p/a-platform-under-pressure-sareptas2025-07-29monthlyhttps://hartajsingh1.substack.com/p/the-deal-window-regulatory-complexity2025-07-24monthlyhttps://hartajsingh1.substack.com/p/gene-editing-between-sci-fi-and-scalability2025-07-21monthlyhttps://hartajsingh1.substack.com/p/biotechs-second-quarter-setup-why2025-07-18monthlyhttps://hartajsingh1.substack.com/p/the-deal-window-jaguar-health-turning2025-07-15monthlyhttps://hartajsingh1.substack.com/p/hope-havoc-and-the-200-day-line2025-07-09monthlyhttps://hartajsingh1.substack.com/p/biotech-in-1h-2025-caught-between2025-07-07monthlyhttps://hartajsingh1.substack.com/p/gileads-re-rating-a-shift-toward2025-07-02monthlyhttps://hartajsingh1.substack.com/p/late-june-pulse-check-conviction2025-06-25monthlyhttps://hartajsingh1.substack.com/p/biogen-flat-now-optionality-ahead2025-06-19monthlyhttps://hartajsingh1.substack.com/p/united-therapeutics-durable-core2025-06-13monthlyhttps://hartajsingh1.substack.com/p/in-this-episode-fda-turbulence-and2025-06-12monthlyhttps://hartajsingh1.substack.com/p/regenerons-reset-path-to-recovery2025-06-09monthlyhttps://hartajsingh1.substack.com/p/regulatory-stress-test-what-fda-cuts2025-06-06monthlyhttps://hartajsingh1.substack.com/p/novavax-in-transition-repositioning2025-05-29monthlyhttps://hartajsingh1.substack.com/p/biotechs-balancing-act-calm-fda-crowded2025-05-27monthlyhttps://hartajsingh1.substack.com/p/the-deal-window-early-stage-innovation2025-05-23monthlyhttps://hartajsingh1.substack.com/p/everyone-hates-biotechwhich-is-usually2025-05-19monthlyhttps://hartajsingh1.substack.com/p/breaking-the-steroid-ceiling-efzofitimod2025-05-13monthlyhttps://hartajsingh1.substack.com/p/biotechs-seasonal-setup-from-q1-slump2025-05-06monthlyhttps://hartajsingh1.substack.com/p/biomea-fusion-a-case-study-in-innovation2025-05-20monthlyhttps://hartajsingh1.substack.com/p/biotechs-bounce-green-shoots-or-head2025-04-29monthlyhttps://hartajsingh1.substack.com/p/pricing-pressure-redux-biopharmas2025-04-25monthlyhttps://hartajsingh1.substack.com/p/biotechs-crossroads-a-reality-check2025-05-01monthlyhttps://hartajsingh1.substack.com/p/immunotherapy-targets-the-surgical2025-04-18monthlyhttps://hartajsingh1.substack.com/p/biotech-buzz-pain-policy-and-potential2025-04-14monthlyhttps://hartajsingh1.substack.com/p/signal-or-noise-biotechs-sentiment2025-04-10monthlyhttps://hartajsingh1.substack.com/p/biotech-capital-compass-video-takeaway2025-04-08monthlyhttps://hartajsingh1.substack.com/p/biotech-at-an-inflection-point-resilience2025-04-08monthlyhttps://hartajsingh1.substack.com/p/biotech-buzz-fast-takes-and-market-5e52025-04-02monthlyhttps://hartajsingh1.substack.com/p/biotech-in-flux-profit-pressure-shrinking2025-04-01monthlyhttps://hartajsingh1.substack.com/p/from-pressure-to-pivot-can-us-biotechs2025-03-30monthlyhttps://hartajsingh1.substack.com/p/surrozen-refocusing-on-ophthalmology2025-03-27monthlyhttps://hartajsingh1.substack.com/p/biotech-buzz-fast-takes-and-market2025-03-23monthlyhttps://hartajsingh1.substack.com/p/from-phds-to-finance-the-biotech2025-03-21monthlyhttps://hartajsingh1.substack.com/p/biotech-watchlist-trevogrumab-a-new2025-03-17monthlyhttps://hartajsingh1.substack.com/p/the-role-of-medical-conferences-in2025-03-13monthlyhttps://hartajsingh1.substack.com/p/akeso-a-biotech-worth-watching2025-03-05monthlyhttps://hartajsingh1.substack.com/p/biotech-capital-compass-video-takeaways-26f2025-03-03monthlyhttps://hartajsingh1.substack.com/p/decoding-roche-a-biotech-giants-next2025-02-27monthlyhttps://hartajsingh1.substack.com/p/drug-development-expert-video-takeaways2025-02-22monthlyhttps://hartajsingh1.substack.com/p/savants-sunday-synthesis-volatility2025-02-17monthlyhttps://hartajsingh1.substack.com/p/biotech-capital-compass-video-takeaways-7602025-02-13monthlyhttps://hartajsingh1.substack.com/p/savants-sunday-synthesis-regenerons2025-02-10monthlyhttps://hartajsingh1.substack.com/p/your-biotech-brief-trends-stocks2025-02-03monthlyhttps://hartajsingh1.substack.com/p/savants-saturday-synthesis-a-busy2025-02-01monthlyhttps://hartajsingh1.substack.com/p/savants-saturday-synthesis-assessing2025-01-26monthlyhttps://hartajsingh1.substack.com/p/your-biotech-brief-curated-takeaways2025-01-24monthlyhttps://hartajsingh1.substack.com/p/sf-bay-biopharma-conferences-key2025-01-20monthlyhttps://hartajsingh1.substack.com/p/biotechs-2025-kickoff-opportunities2025-01-18monthlyhttps://hartajsingh1.substack.com/p/cancer-vaccines-navigating-obstacles2025-01-12monthlyhttps://hartajsingh1.substack.com/p/biotech-capital-compass-video-takeaways-ac62025-01-07monthlyhttps://hartajsingh1.substack.com/p/biotech-weakness-a-harbinger-of-trouble2025-01-03monthlyhttps://hartajsingh1.substack.com/p/biotech-buzz-have-your-say2025-06-15monthlyhttps://hartajsingh1.substack.com/p/how-institutional-investors-analyze2025-02-06monthlyhttps://hartajsingh1.substack.com/p/video-podcast-leading-hiv-innovation2024-12-20monthlyhttps://hartajsingh1.substack.com/p/biotech-challenges-persist-opportunities2025-06-15monthlyhttps://hartajsingh1.substack.com/p/biotech-bellwether-regeneron-a-holiday2025-06-15monthlyhttps://hartajsingh1.substack.com/p/biotech-capital-compass-video-takeaways2024-11-26monthlyhttps://hartajsingh1.substack.com/p/biotech-sell-off-is-the-rfk-jr-effect2025-06-15monthlyhttps://hartajsingh1.substack.com/p/is-the-biotech-sector-showing-signs2025-03-09monthlyhttps://hartajsingh1.substack.com/p/post-us-elections-could-be-interesting2025-06-15monthly